Vaxart Inc
VXRT
Get informed when a big investor buys or sells
+ FollowMarket Cap$133.12M
Close$
$-0.38
173.2% downside
Current Fair Value
173.2% downsideOvervalued by 173.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $133.12 Million |
|---|---|
| Enterprise Value | $90.37 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.07 |
| Beta | 1.09 |
| Outstanding Shares | 240,649,773 |
Return
| Return on Equity | 39.42% |
|---|---|
| Return on Assets | 20.60% |
| Return on Invested Capital | 43.04% |
Valuation & Multiples
| P/E Ratio | 3.57 |
|---|---|
| PEG | -2.68 |
| Price to Sales | 0.52 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 0.35 |
| Enterprise Value to EBIT | 2.03 |
| Enterprise Value to Net Income | 2 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | 0.08 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$0.02
Average shareholder expectationRevenue Estimate
$65.50 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.01%▼ 0.02% |
|---|---|
| Total Invested | $16,243▼ 26.71% |
| Investors Holding | 4▼ 1.00% |
ESG Score
No data
About Vaxart Inc
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can be stored and shipped wit...